Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Purchased by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lifted its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 283.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,922 shares of the company’s stock after acquiring an additional 11,775 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Dr. Reddy’s Laboratories were worth $251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Pinnacle Wealth Planning Services Inc. boosted its stake in shares of Dr. Reddy’s Laboratories by 203.4% in the fourth quarter. Pinnacle Wealth Planning Services Inc. now owns 26,744 shares of the company’s stock worth $422,000 after acquiring an additional 17,930 shares during the last quarter. Lindbrook Capital LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 459.8% in the fourth quarter. Lindbrook Capital LLC now owns 21,621 shares of the company’s stock worth $341,000 after acquiring an additional 17,759 shares during the last quarter. Atria Investments Inc acquired a new stake in shares of Dr. Reddy’s Laboratories in the fourth quarter worth approximately $170,000. Assetmark Inc. boosted its stake in shares of Dr. Reddy’s Laboratories by 443.5% in the fourth quarter. Assetmark Inc. now owns 204,715 shares of the company’s stock worth $3,232,000 after acquiring an additional 167,049 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. Victory Capital Management Inc. now owns 81,460 shares of the company’s stock worth $1,286,000 after acquiring an additional 65,168 shares during the last quarter. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Stock Performance

Shares of Dr. Reddy’s Laboratories stock opened at $12.93 on Monday. Dr. Reddy’s Laboratories Limited has a one year low of $12.62 and a one year high of $16.89. The company has a market cap of $10.79 billion, a price-to-earnings ratio of 20.59 and a beta of 0.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The business’s 50 day moving average price is $14.18 and its 200 day moving average price is $14.92.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, research analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analyst Ratings Changes

RDY has been the topic of a number of research analyst reports. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.